Key Insights

Highlights

Treatment Research

2 treatments under study, led by Betaglucin Soluble Gel 02

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

100%

1 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 3 (1)

Trial Status

Unknown1

Clinical Trials (1)

Showing 1 of 1 trials
NCT03901690Phase 3UnknownPrimary

Betaglucin 0.2% Versus Imiquimod 5% in Treatment of Ano-genital Warts: Combined Results From Triple Blind Controlled Study

Showing all 1 trials

Research Network

Common Treatments

  • Betaglucin Soluble Gel 021
  • Imiquimod1

Active Sponsors

  • Bioanalisis1
  • CALOX Laboratories1
  • Centro de Investigaciones Medicas y Ensayos Clinicos Dr Italo Fabbri1

Top Investigators

Activity Timeline